Joseph Woodard
Chief Tech/Sci/R&D Officer at IMUGENE LIMITED
Profile
Joseph Paul Woodard is currently the Chief Medical Officer at Imugene Ltd.
He previously worked as the Senior Vice President-Clinical & Medical Affairs at Bellicum Pharmaceuticals, Inc. from 2017 to 2019.
He also served as the Chief Medical Officer & Senior Vice President at Immune-Onc Therapeutics, Inc. Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and his doctorate from UNC School of Medicine.
Joseph Woodard active positions
Companies | Position | Start |
---|---|---|
IMUGENE LIMITED | Chief Tech/Sci/R&D Officer | 03/09/2023 |
Former positions of Joseph Woodard
Companies | Position | End |
---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/10/2019 |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Joseph Woodard
The University of North Carolina at Charlotte | Undergraduate Degree |
UNC School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
IMUGENE LIMITED | Health Technology |
Private companies | 2 |
---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Health Technology |
- Stock Market
- Insiders
- Joseph Woodard